RPL13AP25

Across TCGA pan-cancer cohorts, RPL13AP25 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPL13AP25’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL13AP25 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL13AP25 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

KIRC, KIRP, and LIHC are the cancer types where RPL13AP25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL13AP25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.897	<.001	12	view →
KIRP	All	II,III,IV	+0.678	<.001	10	view →
LIHC	Female	II,III,IV	+1.320	<.001	7	view →
COAD	All	II,III,IV	+0.582	<.001	6	view →
CHOL	Male	All	+2.096	<.001	5	view →
BRCA	Female	All	−0.373	<.001	4	view →
STAD	All	IV	+0.826	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPL13AP25–KIRC

Open the KIRC breakdown →